We served as healthcare regulatory counsel to Parthenon Capital, a growth-oriented private equity firm, in its investment in RxSense, a high-growth healthcare technology company that utilizes its proprietary technology platform to provide innovative prescription savings solutions to consumers and pharmacy benefits administration and analytics to enterprise customers. Terms of the transaction were not disclosed.
Parthenon Capital Invests in RxSense
You Also May Be Interested In:
Advise a public university system on compliance with the rules associated with grants and contracts from NIH, NSF, and the Department of Defense
Representation of Lead Capital Partners, a multi-family sponsored private equity firm, in its acquisition of Ladd Dental Group, Inc., a dental service provider with six locations throughout central Indiana
Lead Counsel to POINT Biopharma Inc. in its Proposed SPAC Business Combination with Research Alliance Corp. I
Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management. Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.